SK Bioscience takes majority stake in CDMO for $244M; Ex-Lonza CEO joins Cytiva

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

SK Bioscience now has a 60% stake in the CDMO IDT Biologika after signing a deal with German pharma company Klocke, in a deal worth 339 billion Korean won ($244 million). Klocke will retain a 40% share in the CDMO, according to a Thursday release.

Lonza’s former CEO Pierre-Alain Ruffieux is joining Cytiva as its new chief operating officer effective July, according to a Thursday release. This is a newly created role for Ruffieux, who left Lonza in September 2023. Ruffieux will be responsible for improving the customer experience and engagement at Cytiva.

“[Ruffieux] brings unparalleled experience and a deep understanding of how suppliers positively impact the success of our pharmaceutical and biotechnology customers,” Cytiva’s CEO Chris Riley told Endpoints…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks